@KRob8753 @alli_naquin @onein300 @pjgreen @brainmatters10 Eric Macklin uses this example for post-hoc in the CRLI - https://t.co/AxFPhHxCMs that illustrates an example. Also I encourage anyone to look at Fig 3 of the reldesemtiv P2 paper - lots of good …
18/ Finally, a Reldesemtiv P2 ALS Trial https://t.co/j3fIHpHVbm had placebo n=115, age=59.6, time since symptom onset=22.1 months, and a -3.5 change over 3 months for a -1.16 change per month. About equivalent to the average change for AMX0035(Thought s…
As reported at the Perth meeting, a phase 2 trial Of Reldesemtiv did not significantly improve functional outcome measures at all dose levels https://t.co/XwIAV3n4xH
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With #ALS #MND https://t.co/BDaekTklNS